SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's Laboratories Ltd has received permission to sell Quetiapine in New Zealand from Pharmac, the drug-funding agency of New Zealand Government. Quetiapine is a drug indicated for treatment of manic and depressive dimensions of bipolar disorder. The drug would be introduced in New Zealand market from October 1 and Pharmac would fully fund (completely reimburse the expenses incurred) the drug made Dr Reddy’s.

 

Dr Reddy's would be the third player selling the drug, apart from the two existing suppliers including AstraZeneca. During last financial year, the company earned $7 million revenue from New Zealand. Dr Reddy's was actively working in New Zealand market and had plans to increase its presence in the coming months.

crackcrack

Dr. Reddys Lab Share Price

1234.85 2.85 (0.23%)
13-Apr-2026 15:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1234.85
Cipla 1211.95
Zydus Lifesciences 923.25
Lupin 2315.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×